Outcome of Board Meeting - Appointment of Additional Director
Caplin Point Laboratories Ltd has informed BSE that the Board of Directors of the Company at their meeting held on November 09, 2016, appointed Mr. D Sathyanarayanan as an Additional Director (Non-Executive - Independent) with effect from November 09, 2016. Standalone & Consolidated Financial Results, Limited Review Report for September 30, 2016
Caplin Point Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Consolidated Financial Results for the period ended September 30, 20163. Standalone Limited Review for the period ended September 30, 20164. Consolidated Limited Review for the period ended September 30, 2016 US FDA inspection completed at Caplin Point's Injectable site
Caplin Point Laboratories Ltd has informed BSE regarding "US FDA inspection completed at Caplin Point's Injectable site". Shareholding for the Period Ended October 20, 2016
Caplin Point Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended October 20, 2016. For more details, kindly Click here Caplin Point Lab zooms over 40% in three days post stock split
The stock hit a record high of Rs 414, rallied 42% in past three trading sessions from Rs 291 on October 18, 2016. Board Meeting Intimation for Results & Closure of Trading Window
Caplin Point Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on November 09, 2016, inter alia, to consider, approve and take on record the Un-audited Financial Results for the quarter/half year ended September 30, 2016.Accordingly, the Trading Window for dealing in the equity shares of the Company will remain closed for Promoters, Directors, other Connected Persons and Employees... Shareholding for the Period Ended September 30, 2016
Caplin Point Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Caplin Point Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Fixes Record Date for Stock Split
Caplin Point Laboratories Ltd has informed BSE that October 20, 2016 has been fixed as the RECORD DATE for the purpose of ascertaining the eligible members who would be entitled to receive 5 (Five) equity shares of nominal face value of Rs. 2/- in lieu of 1 (One) existing equity snare of nominal face value of Rs. 10/- each of the Company. Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Caplin Point Laboratories Ltd has informed BSE regarding the details of Voting results at the Annual General Meeting (AGM) of the Company held on September 12, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report.